Trial Profile
Phase 3, Multi-Center, Randomized, Double-Blind, Parallel-Arm, 52-Week Dose Comparison Study of the Efficacy and Safety of 25 mg QD and 50 mg QD of OPC-6335 Oral Tablets and 800 mg BID of Asacol® in the Maintenance of Ulcerative Colitis Remission
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Aug 2022
Price :
$35
*
At a glance
- Drugs Tetomilast (Primary) ; Mesalazine
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Acronyms CORE
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 12 May 2014 New trial record
- 20 Jun 2007